FRI0571 OSTEOPOROSIS AND BREAST CANCER: CAN FRAX-BASED RISK FACTORS ACCURATELY PREDICT FURTHER FRACTURES AT THIS SETTING?
S. Lopez-Salguero 1,1 , J. Background: Women with breast cáncer (BC) are at risk for the development of bone loss and osteoporosis (OP) mainly due to adjuvant therapies, as aromatase inhibitors (AI). Thus, it would be of special interest in this group of patientes, to know at baseline wich factors can predispose to develope fragility fractures (FF) during follow-up, in order to optmize vigilance and treatment. Objectives: The purpose of this study is to analyze wich risk factors at baseline that can predict the appereance of a new FF in women with BC and OP.
Methods: Retrospective analysis of consecutive female patients with recent breast cancer (BC) and low bone mineral density (BMD) referred to the osteoporosis outpatient clinic for assessment, as agreed with oncologists. Fort he purpose of this anaylisis, only patients with follow-up data (at least six months after baseline visit) were selected. FRAX tool [1]-derived risk factors (age, BMI, DEXA, previous fracture, parent fractured hip, smoking, alcohol, glucocorticoids, rheumatoid arthritis, secondary OP) were taken as explicative variables. Student's t and chi-2 tests were used to perform comparisons base don the appereance of new FF in the study period. Results: A total number of 156 female patients have been assessed up to January 2017. Of the 107 patients in follow-up (68.5%; median time in follow-up 2.1 years p25-75 1.2-3.2). Median age was 62.07 years old (SD±10,35), being 89% of them postmenopausal. 73 (68,2%) were on AI therapy (10 anastrozole, 59 letrozole and 4 exemestane). At baseline, 29 patients (27.1%) showed a FF (15 vertebral; 10 non vertebral; 2 hip; 2 multiple fracture). Antiosteoporotic treatment was recommended in 95 patients (88.7%). During follow-up, 13 FF were seen (12,1%; CI95% 6-19); being 8 of them vertebral, 4 not vertebral, and one multiple fracture; no new hip FF was seen. After comparison of the different risk factors according to the development of a new FF, no significant association was found (see table) . Background: In the busy clinic, identifying individuals at high fracture (fx) risk who warrant intervention can be a challenge. There are several medical conditions that increase the risk for bone loss and falls which are recorded in the electronic medical record (EMR). Objectives: We explored whether we could exploit data available in the EMR to estimate FRAX treatment thresholds to help passively identify patients who would benefit from further bone mineral density screening and management. Methods: We studied 912 women and men, previously recruited for our bone health studies, in whom FRAX scores (with and without BMD) had been determined and comprehensive medical diagnoses were available through the medical linkage system of the Rochester Epidemiology Project. All diagnoses were categorized by the Clinical Classification Software (CCS) system whereby over 14,000 ICD-9-CM diagnoses are reduced to 568 clinically meaningful categories. If a subject had at least two diagnoses in a CCS category that were at least 30 days apart and within 5 years of their FRAX assessment, the subject was treated as having that CCS code. We used Gradient Boosting Machine (GBM) to create models that would predict the treatment thresholds for the FRAX 10-year risk for major osteoporotic (OP) fx (>20%) and hip fx (>3%), based on available diagnoses. Models were fit using age, sex and CCS category from 80% of the data, retaining 20% for validation. Results: Of the 564 (62%) women and 348 (38%) men, the mean ± SD age was 61±16 yrs. There were no significant differences in subject characteristics used for FRAX calculation or FRAX scores between the training and validation sets. The c-statistic for GBM models predicting treatment thresholds for FRAX, calculated with BMD, for major OP fx and hip fx were 0.95 and 0.96, respectively, for the training set, and 0.88 and 0.94 for the validation set. Similar results were observed for FRAX scores without BMD. Conclusions: FRAX treatment thresholds may be reasonably estimated from data available in the EMR to help identify to the clinician those at highest risk for fracture who would warrant further evaluation. Further work to implement and validate these findings in the EMR system would be necessary. Background: Mechanisms underlying osteoporosis in chronic cholestasis are complex and poorly understood. In this setting, osteoporosis mainly results from low bone formation, related to the effects of retained substances of cholestasis, such as bilirubin and bile acids. Thus, in "in vitro" studies, unconjugated bilirubin and serum from jaundiced patients decrease osteoblast viability, differentiation and mineralization. However, the influence of cholestasis on osteocytes, the most ubiquitous cells of the skeleton, is unknown. Objectives: The aim of this study was to analyze the direct effects of increased molecules of cholestasis, such as bilirubin (Bil) and lithocholic acid (LCA), and the potential protective effect of ursodeoxycholic acid (UDCA) on the osteocytes. Methods: MLO-Y4 and MLO-A5 osteocyte cell lines treated at different times and concentrations with Bil, LCA and UDCA were used to determine: 1) Viability: WST colorimetric method; 2) Differentiation: quantification of alkaline phosphatase (AP) activity; 3) Mineralization: Alizarin red staining quantification; and 4) Apoptosis: quantification of DNA fragmentation and caspase-3 activity. Results: LCA (100μM) and Bil (50μM) significantly decreased viability in MLO-Y4 from 72 hours (10%) and 48 hours (11%), respectively (p≤0.01), and Bil decreased viability (49%) in MLO-A5 from 96 hours (p<0.01). Bil decreased AP activity by 47% after 96 hours, under conditions of differentiation in MLO-Y4 (p≤0.01). There were no effects on AP activity in MLO-A5. After 14 days, Bil was associated with a significant mineralization decrease, as high as 87%, in MLO-A5 (p≤0.02). Moreover, Bil and LCA increased apoptosis in MLO-Y4, determined by DNA fragmentation (242% and 119%, respectively) and caspase-3 activity (190% and 251%, respectively) (p≤0.01) after 24 hours. In contrast, UDCA (100 μM) increased viability after 72 hours (11%) and decreased the deleterious effects of LCA or BiI (p≤0.02). UDCA increased AP activity in MLO-Y4 after 72 hours under growth conditions (p=0.018), and after 24 hours under differentiation conditions (p≤0.01). Conclusions: Bilirubin and lithocholic acid have damaging effects on osteocytic cells decreasing viability, differentiation and mineralization, and increasing apoptosis, effects that are neutralized by the UDCA. These results indicate that substances retained in cholestasis impair osteocytic functions, and therefore may be involved in the pathogenesis of osteoporosis in cholestatic diseases. Objectives: To compair two questionaires:a specific one-Osteoporosis Quality of Life Questionnaire (OQLQ) and a general one-Short Form-36 (SF-36),in women with decreased mineral bone density (BMD) and vertebral fractures,and to estimate which one is more useful for everyday work. Methods: Cross-section study included 50 menopausal women with osteoporosis (OP), who were assessed with the general questionaire,and all known risk factors for osteoporosis were confirmed. Osteodensitometry scan (DXA) was performed on lumbar spine,and based both on T index value and BMD the subjects were divided in two groups:first grour (women with OP, n=25),second group (women with fractures of spinal vertebra due to OP,regardless of BMD, n=25, and with at least 4 months since the last fracture).The quality of life was assessed by two questionaires:a specific one OQLQ-consists of 30 questions divided into 5 areas,which are evaluated from 1 to 7 (the lower the score the more sever function damage and worse quality of life) and the general questionnaire SF-36-containing 36 questions divided into 8 areas (scores from 0 to 100, where the lower value is also a poorer quality of life).Questionnaires were converted to get two summarized scales,so as to obtain the total score for:physical (PCS) and mental functions (MCS).The two questionnaires were compared using appropriate statistical methods in SPSS. Results: There was no significant differencev between groups regarding: mean age (first=63.3±6.0, second=64.9±7.8),mean age at the start of the menopause (first=46.8±5.3, second=48.2±4.2 years), mean duration of menopause (first=16.4±6.9, second=17.1±6.9 year),but there was statistically significant difference between the number of risk factors for OP (first=1.8±1.2, second=2.8±0.9, p<0.01).Statistically significant between group difference (p<0.01) in mean BMD and T score (first-BMD 0.807±0.057gr/cm 2 ,T scor -3.12±0.49SD, second-BMD 0.931±0.172 gr/cm 2 ,T score -2.09±1.45SD).The following DXA values were measured in the second group:8 patients-normal,6-osteopenia,11-osteoporosis,with average number of fractures 2.6±0. During the mean 12-month follow-up period, there were no unexpected adverse event [AE] or severe adverse event, no graft failure and no deaths. No patient experienced fracture. Only one patient presented an infectious AE with recurrent cutaneous abscess. Renal function remained stable with no difference in serum creatinine between baseline and 12 months for the majority of the kidney transplant recipients. However, 9 recipients experienced a decrease in renal function with a mean increased in serum creatinine of 32.5micromol/L between baseline and 12 months. Serum calcium was stable, no hypocalcaemia was observed. Among patients with normal baseline PTH, two presented hyperparathyroidism during the follow-up period. Among the 11 patients with baseline hyperparathyroidism, 7 had an increased PTH level between baseline and 12 months. None were initiated on cinacalcet. Conclusions: Our results suggest that denosumab is safe in kidney transplant recipients. We did not observe an increase in the infection rates, nor hypocalcemia. However, several patients experienced a decrease in their renal function or an increased hyperparathyroidism. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6899 
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